These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23157627)

  • 1. Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia.
    Sumiyoshi T; Higuchi Y
    Curr Med Chem; 2013; 20(3):357-62. PubMed ID: 23157627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia.
    Sumiyoshi T; Higuchi Y; Uehara T
    Front Behav Neurosci; 2013 Oct; 7():140. PubMed ID: 24137114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.
    Schreiber R; Newman-Tancredi A
    Neurobiol Learn Mem; 2014 Apr; 110():72-80. PubMed ID: 24423786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.
    Wierońska JM; Sławińska A; Stachowicz K; Łasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A
    Behav Brain Res; 2013 Nov; 256():298-304. PubMed ID: 23948211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.
    Roth BL; Hanizavareh SM; Blum AE
    Psychopharmacology (Berl); 2004 Jun; 174(1):17-24. PubMed ID: 15205874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
    Sun H; Zhu L; Yang H; Qian W; Guo L; Zhou S; Gao B; Li Z; Zhou Y; Jiang H; Chen K; Zhen X; Liu H
    Bioorg Med Chem; 2013 Feb; 21(4):856-68. PubMed ID: 23332346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
    Millan MJ
    J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.
    Ohno Y
    CNS Neurosci Ther; 2011 Feb; 17(1):58-65. PubMed ID: 21091640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.
    Yamada R; Wada A; Stickley A; Yokoi Y; Sumiyoshi T
    Int J Neuropsychopharmacol; 2023 Apr; 26(4):249-258. PubMed ID: 36721972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
    Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism.
    Horiguchi M; Miyauchi M; Neugebauer NM; Oyamada Y; Meltzer HY
    Behav Brain Res; 2016 Mar; 301():132-41. PubMed ID: 26342283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor.
    Haleem DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():170-80. PubMed ID: 23906987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism.
    McCreary AC; Jones CA
    Curr Pharm Des; 2010; 16(5):516-21. PubMed ID: 19909230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
    Terranova JP; Chabot C; Barnouin MC; Perrault G; Depoortere R; Griebel G; Scatton B
    Psychopharmacology (Berl); 2005 Aug; 181(1):134-44. PubMed ID: 15830220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.